Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder

To develop effect sizes for 3 mood stabilizers-lithium, divalproex sodium, and carbamazepine-for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Child and Adolescent Psychiatry 2000-06, Vol.39 (6), p.713-720
Hauptverfasser: KOWATCH, ROBERT A., SUPPES, TRISHA, CARMODY, THOMAS J., BUCCI, JOHN P., HUME, JUDITH H., KROMELIS, MICHELLE, EMSLIE, GRAHAM J., WEINBERG, WARREN A., RUSH, A. JOHN
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 720
container_issue 6
container_start_page 713
container_title Journal of the American Academy of Child and Adolescent Psychiatry
container_volume 39
creator KOWATCH, ROBERT A.
SUPPES, TRISHA
CARMODY, THOMAS J.
BUCCI, JOHN P.
HUME, JUDITH H.
KROMELIS, MICHELLE
EMSLIE, GRAHAM J.
WEINBERG, WARREN A.
RUSH, A. JOHN
description To develop effect sizes for 3 mood stabilizers-lithium, divalproex sodium, and carbamazepine-for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Using a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ22 = 0.85, p = .60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Divalproex sodium, lithium, and carbamazepine all showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.
doi_str_mv 10.1097/00004583-200006000-00009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71176401</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0890856709662407</els_id><sourcerecordid>54858070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-714dfa26e03a541433adf09fc0bd20ed840531d5463586d25ab590ceb75438f33</originalsourceid><addsrcrecordid>eNqFUU1v3CAQRVWjZLPJX6hQDz3VDRiw8THZ5qPSSjlsohwRNoNCZMMW7CjNry_7karKJUgjRsObN_N4CGFKflDS1GckHy4kK8pNVuUoNknzCc2oKOtCcCo_oxmRDSmkqOojdJzSU0bQWspDdESJ5BUjYob8pbXQjXjlXgEHi5dufHTT8B3_dM-6X8cAL3gVzLakvcELHVs96FdYOw_Yebx4dL2J4Lev5yb0kDrwY8IPmQlfuHXodcxsKUQD8QQdWN0nON3fc3R_dXm3uCmWt9e_FufLouNlNRY15cbqsgLCdNbCGdPGksZ2pDUlASM5EYwakUUIWZlS6FY0pIO2FpxJy9gcfdvxZgW_J0ijGlzeq--1hzAlVVNaV5zQDPz6DvgUpujzbqqkZcWazaQ5kjtQF0NKEaxaRzfo-EdRojaGqDdD1D9DtqUmt37Z80_tAOa_xp0DGXCxA0D-jmcHUaXOge_AuJiNUSa4j6f8BT06mPE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212639405</pqid></control><display><type>article</type><title>Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Journals@Ovid Complete</source><creator>KOWATCH, ROBERT A. ; SUPPES, TRISHA ; CARMODY, THOMAS J. ; BUCCI, JOHN P. ; HUME, JUDITH H. ; KROMELIS, MICHELLE ; EMSLIE, GRAHAM J. ; WEINBERG, WARREN A. ; RUSH, A. JOHN</creator><creatorcontrib>KOWATCH, ROBERT A. ; SUPPES, TRISHA ; CARMODY, THOMAS J. ; BUCCI, JOHN P. ; HUME, JUDITH H. ; KROMELIS, MICHELLE ; EMSLIE, GRAHAM J. ; WEINBERG, WARREN A. ; RUSH, A. JOHN</creatorcontrib><description>To develop effect sizes for 3 mood stabilizers-lithium, divalproex sodium, and carbamazepine-for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Using a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ22 = 0.85, p = .60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Divalproex sodium, lithium, and carbamazepine all showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1097/00004583-200006000-00009</identifier><identifier>PMID: 10846305</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute Disease ; Adolescent ; Age Factors ; Antidepressants ; Antimanic Agents - pharmacology ; Antimanic Agents - therapeutic use ; bipolar disorder ; Bipolar Disorder - drug therapy ; carbamazepine ; Carbamazepine - pharmacology ; Carbamazepine - therapeutic use ; Child ; Children &amp; youth ; divalproex sodium ; Dose-Response Relationship, Drug ; Drug therapy ; effect size ; Female ; Humans ; lithium ; Lithium - pharmacology ; Lithium - therapeutic use ; Male ; Mental disorders ; Outpatients - statistics &amp; numerical data ; Pilot Projects ; Psychiatric Status Rating Scales ; Teenagers ; Valproic Acid - pharmacology ; Valproic Acid - therapeutic use</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 2000-06, Vol.39 (6), p.713-720</ispartof><rights>2000 The American Academy of Child and Adolescent Psychiatry</rights><rights>Copyright Lippincott Williams &amp; Wilkins Jun 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-714dfa26e03a541433adf09fc0bd20ed840531d5463586d25ab590ceb75438f33</citedby><cites>FETCH-LOGICAL-c426t-714dfa26e03a541433adf09fc0bd20ed840531d5463586d25ab590ceb75438f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1097/00004583-200006000-00009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,30999,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10846305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOWATCH, ROBERT A.</creatorcontrib><creatorcontrib>SUPPES, TRISHA</creatorcontrib><creatorcontrib>CARMODY, THOMAS J.</creatorcontrib><creatorcontrib>BUCCI, JOHN P.</creatorcontrib><creatorcontrib>HUME, JUDITH H.</creatorcontrib><creatorcontrib>KROMELIS, MICHELLE</creatorcontrib><creatorcontrib>EMSLIE, GRAHAM J.</creatorcontrib><creatorcontrib>WEINBERG, WARREN A.</creatorcontrib><creatorcontrib>RUSH, A. JOHN</creatorcontrib><title>Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><description>To develop effect sizes for 3 mood stabilizers-lithium, divalproex sodium, and carbamazepine-for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Using a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ22 = 0.85, p = .60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Divalproex sodium, lithium, and carbamazepine all showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.</description><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Age Factors</subject><subject>Antidepressants</subject><subject>Antimanic Agents - pharmacology</subject><subject>Antimanic Agents - therapeutic use</subject><subject>bipolar disorder</subject><subject>Bipolar Disorder - drug therapy</subject><subject>carbamazepine</subject><subject>Carbamazepine - pharmacology</subject><subject>Carbamazepine - therapeutic use</subject><subject>Child</subject><subject>Children &amp; youth</subject><subject>divalproex sodium</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>effect size</subject><subject>Female</subject><subject>Humans</subject><subject>lithium</subject><subject>Lithium - pharmacology</subject><subject>Lithium - therapeutic use</subject><subject>Male</subject><subject>Mental disorders</subject><subject>Outpatients - statistics &amp; numerical data</subject><subject>Pilot Projects</subject><subject>Psychiatric Status Rating Scales</subject><subject>Teenagers</subject><subject>Valproic Acid - pharmacology</subject><subject>Valproic Acid - therapeutic use</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFUU1v3CAQRVWjZLPJX6hQDz3VDRiw8THZ5qPSSjlsohwRNoNCZMMW7CjNry_7karKJUgjRsObN_N4CGFKflDS1GckHy4kK8pNVuUoNknzCc2oKOtCcCo_oxmRDSmkqOojdJzSU0bQWspDdESJ5BUjYob8pbXQjXjlXgEHi5dufHTT8B3_dM-6X8cAL3gVzLakvcELHVs96FdYOw_Yebx4dL2J4Lev5yb0kDrwY8IPmQlfuHXodcxsKUQD8QQdWN0nON3fc3R_dXm3uCmWt9e_FufLouNlNRY15cbqsgLCdNbCGdPGksZ2pDUlASM5EYwakUUIWZlS6FY0pIO2FpxJy9gcfdvxZgW_J0ijGlzeq--1hzAlVVNaV5zQDPz6DvgUpujzbqqkZcWazaQ5kjtQF0NKEaxaRzfo-EdRojaGqDdD1D9DtqUmt37Z80_tAOa_xp0DGXCxA0D-jmcHUaXOge_AuJiNUSa4j6f8BT06mPE</recordid><startdate>20000601</startdate><enddate>20000601</enddate><creator>KOWATCH, ROBERT A.</creator><creator>SUPPES, TRISHA</creator><creator>CARMODY, THOMAS J.</creator><creator>BUCCI, JOHN P.</creator><creator>HUME, JUDITH H.</creator><creator>KROMELIS, MICHELLE</creator><creator>EMSLIE, GRAHAM J.</creator><creator>WEINBERG, WARREN A.</creator><creator>RUSH, A. JOHN</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20000601</creationdate><title>Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder</title><author>KOWATCH, ROBERT A. ; SUPPES, TRISHA ; CARMODY, THOMAS J. ; BUCCI, JOHN P. ; HUME, JUDITH H. ; KROMELIS, MICHELLE ; EMSLIE, GRAHAM J. ; WEINBERG, WARREN A. ; RUSH, A. JOHN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-714dfa26e03a541433adf09fc0bd20ed840531d5463586d25ab590ceb75438f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Age Factors</topic><topic>Antidepressants</topic><topic>Antimanic Agents - pharmacology</topic><topic>Antimanic Agents - therapeutic use</topic><topic>bipolar disorder</topic><topic>Bipolar Disorder - drug therapy</topic><topic>carbamazepine</topic><topic>Carbamazepine - pharmacology</topic><topic>Carbamazepine - therapeutic use</topic><topic>Child</topic><topic>Children &amp; youth</topic><topic>divalproex sodium</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>effect size</topic><topic>Female</topic><topic>Humans</topic><topic>lithium</topic><topic>Lithium - pharmacology</topic><topic>Lithium - therapeutic use</topic><topic>Male</topic><topic>Mental disorders</topic><topic>Outpatients - statistics &amp; numerical data</topic><topic>Pilot Projects</topic><topic>Psychiatric Status Rating Scales</topic><topic>Teenagers</topic><topic>Valproic Acid - pharmacology</topic><topic>Valproic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KOWATCH, ROBERT A.</creatorcontrib><creatorcontrib>SUPPES, TRISHA</creatorcontrib><creatorcontrib>CARMODY, THOMAS J.</creatorcontrib><creatorcontrib>BUCCI, JOHN P.</creatorcontrib><creatorcontrib>HUME, JUDITH H.</creatorcontrib><creatorcontrib>KROMELIS, MICHELLE</creatorcontrib><creatorcontrib>EMSLIE, GRAHAM J.</creatorcontrib><creatorcontrib>WEINBERG, WARREN A.</creatorcontrib><creatorcontrib>RUSH, A. JOHN</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOWATCH, ROBERT A.</au><au>SUPPES, TRISHA</au><au>CARMODY, THOMAS J.</au><au>BUCCI, JOHN P.</au><au>HUME, JUDITH H.</au><au>KROMELIS, MICHELLE</au><au>EMSLIE, GRAHAM J.</au><au>WEINBERG, WARREN A.</au><au>RUSH, A. JOHN</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><date>2000-06-01</date><risdate>2000</risdate><volume>39</volume><issue>6</issue><spage>713</spage><epage>720</epage><pages>713-720</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>To develop effect sizes for 3 mood stabilizers-lithium, divalproex sodium, and carbamazepine-for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Using a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ22 = 0.85, p = .60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Divalproex sodium, lithium, and carbamazepine all showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>10846305</pmid><doi>10.1097/00004583-200006000-00009</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0890-8567
ispartof Journal of the American Academy of Child and Adolescent Psychiatry, 2000-06, Vol.39 (6), p.713-720
issn 0890-8567
1527-5418
language eng
recordid cdi_proquest_miscellaneous_71176401
source Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elsevier ScienceDirect Journals Complete; Journals@Ovid Complete
subjects Acute Disease
Adolescent
Age Factors
Antidepressants
Antimanic Agents - pharmacology
Antimanic Agents - therapeutic use
bipolar disorder
Bipolar Disorder - drug therapy
carbamazepine
Carbamazepine - pharmacology
Carbamazepine - therapeutic use
Child
Children & youth
divalproex sodium
Dose-Response Relationship, Drug
Drug therapy
effect size
Female
Humans
lithium
Lithium - pharmacology
Lithium - therapeutic use
Male
Mental disorders
Outpatients - statistics & numerical data
Pilot Projects
Psychiatric Status Rating Scales
Teenagers
Valproic Acid - pharmacology
Valproic Acid - therapeutic use
title Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A42%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20Size%20of%20Lithium,%20Divalproex%20Sodium,%20and%20Carbamazepine%20in%20Children%20and%20Adolescents%20With%20Bipolar%20Disorder&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=KOWATCH,%20ROBERT%20A.&rft.date=2000-06-01&rft.volume=39&rft.issue=6&rft.spage=713&rft.epage=720&rft.pages=713-720&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1097/00004583-200006000-00009&rft_dat=%3Cproquest_cross%3E54858070%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212639405&rft_id=info:pmid/10846305&rft_els_id=S0890856709662407&rfr_iscdi=true